Thus NfL has become an already established biomarker for neuronal injury and as a surrogate parameter for disease activity in neurodegenerative diseases, such as ALS, Parkinson's disease, and in multiple sclerosis. This evidence concerns the gene NEFL and neurodegenerative disease.